SYROS PHARMACEUTICALS INC (SYRS) Stock Price, Forecast & Analysis
USA - NASDAQ:SYRS - US87184Q2066 - Common Stock
SYRS Key Statistics, Chart & Performance
The current stock price of SYRS is 0.1172 USD. In the past month the price decreased by -34.71%. In the past year, price decreased by -98.13%.
SYRS Latest News, Press Relases and Analysis
SYRS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 20.59 | 385.18B | ||
| AMGN | AMGEN INC | 13.68 | 160.66B | ||
| GILD | GILEAD SCIENCES INC | 14.63 | 148.64B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.12 | 109.11B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.48 | 69.08B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 350.8 | 59.78B | ||
| ARGX | ARGENX SE - ADR | 61.77 | 50.39B | ||
| INSM | INSMED INC | N/A | 40.08B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.01 | 34.10B | ||
| NTRA | NATERA INC | N/A | 27.30B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.98B | ||
| BIIB | BIOGEN INC | 9.22 | 22.62B |
Related stock screener links
About SYRS
Company Profile
Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 68 full-time employees. The company went IPO on 2016-06-30. The firm is focused on developing new standards of care for the frontline treatment of patients with hematologic malignancies. The firm is advancing Tamibarotene, a selective retinoic acid receptor alpha (RARα), agonist for which the Company is conducting SELECT-MDS-1, a Phase III clinical trial evaluating tamibarotene in combination with azacitidine in a genomically defined subset of patients with higher-risk myelodysplastic syndrome (HR-MDS), and for which it is conducting SELECT-AML-1, a randomized Phase II clinical trial evaluating tamibarotene in combination with venetoclax and azacitidine in a genomically defined subset of newly diagnosed patients with acute myeloid leukemia (AML). Its other assets include SY-2101 and SY-5609. The firm is seeking out-licensing opportunities for the further development of SY-5609, its highly selective and potent inhibitor of cyclin dependent kinase 7 (CDK7).
Company Info
SYROS PHARMACEUTICALS INC
35 Cambridge Park Drive
Cambridge MASSACHUSETTS 02140 US
CEO: Nancy Simonian
Employees: 68
Phone: 16177441340
SYROS PHARMACEUTICALS INC / SYRS FAQ
What does SYROS PHARMACEUTICALS INC do?
Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 68 full-time employees. The company went IPO on 2016-06-30. The firm is focused on developing new standards of care for the frontline treatment of patients with hematologic malignancies. The firm is advancing Tamibarotene, a selective retinoic acid receptor alpha (RARα), agonist for which the Company is conducting SELECT-MDS-1, a Phase III clinical trial evaluating tamibarotene in combination with azacitidine in a genomically defined subset of patients with higher-risk myelodysplastic syndrome (HR-MDS), and for which it is conducting SELECT-AML-1, a randomized Phase II clinical trial evaluating tamibarotene in combination with venetoclax and azacitidine in a genomically defined subset of newly diagnosed patients with acute myeloid leukemia (AML). Its other assets include SY-2101 and SY-5609. The firm is seeking out-licensing opportunities for the further development of SY-5609, its highly selective and potent inhibitor of cyclin dependent kinase 7 (CDK7).
Can you provide the latest stock price for SYROS PHARMACEUTICALS INC?
The current stock price of SYRS is 0.1172 USD. The price decreased by -8.44% in the last trading session.
Does SYRS stock pay dividends?
SYRS does not pay a dividend.
What is the ChartMill technical and fundamental rating of SYRS stock?
SYRS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Can you provide the number of employees for SYROS PHARMACEUTICALS INC?
SYROS PHARMACEUTICALS INC (SYRS) currently has 68 employees.
Can you provide the ownership details for SYRS stock?
You can find the ownership structure of SYROS PHARMACEUTICALS INC (SYRS) on the Ownership tab.
Can you provide the short interest for SYRS stock?
The outstanding short interest for SYROS PHARMACEUTICALS INC (SYRS) is 0.2% of its float.
SYRS Technical Analysis
SYRS Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to SYRS. SYRS has a bad profitability rating. Also its financial health evaluation is rather negative.
SYRS Financial Highlights
Over the last trailing twelve months SYRS reported a non-GAAP Earnings per Share(EPS) of -3.03. The EPS increased by 19.2% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -115.08% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
SYRS Forecast & Estimates
9 analysts have analysed SYRS and the average price target is 10.71 USD. This implies a price increase of 9038.23% is expected in the next year compared to the current price of 0.1172.
For the next year, analysts expect an EPS growth of 73.44% and a revenue growth -100% for SYRS